Compass Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
19.6%projected annual EPS growth
Analyst Coverage
12analysts covering
FY EPS (est.)
-$0.48next fiscal year
Monitoring Framework
Key Performance Indicators
Tovecimig (CTX-009) Overall Response Rate (ORR) in COMPANION-002 Annually1,710.0%Target: Statistically significant improvement vs paclitaxel alone (~5%)
Tovecimig (CTX-009) Median Progression-Free Survival (PFS) in COMPANION-002 Annually4.7Target: Statistically significant improvement vs paclitaxel alone (2.6 months)
Cash and Marketable Securities Quarterly195MTarget: Sufficient liquidity to fund operations into 2028
Watch Items
- FDA Regulatory Alignment and BLA Submission Pathway for TovecimigTrigger: FDA feedback on the confounding effects of the 54% crossover rate on Overall Survival (OS) dataAction: Determine if the FDA will accept the BLA filing based on PFS and ORR endpoints or require a confirmatory trial
- CTX-8371 Phase 1 Expansion Cohort DataTrigger: Initial clinical efficacy and safety readouts in NSCLC, TNBC, and Hodgkin lymphomaAction: Evaluate therapeutic signal in post-checkpoint inhibitor settings to guide Phase 2 development
- CTX-10726 Phase 1 Dose-Escalation StudyTrigger: Initial safety and pharmacokinetic data expected in Q4 2026Action: Assess dose-limiting toxicities and establish recommended Phase 2 dose
Research as of 19 Jun 2026